Log in
NYSE:MYOV

Myovant Sciences News Headlines

$23.53
+1.68 (+7.69 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$21.99
Now: $23.53
$23.66
50-Day Range
$13.80
MA: $16.74
$21.85
52-Week Range
$5.98
Now: $23.53
$23.66
Volume598,309 shs
Average Volume1.05 million shs
Market Capitalization$2.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.6

Headlines

Myovant Sciences (NYSE MYOV) News Headlines Today

Source:
SourceHeadline
Myovant Sciences (NYSE:MYOV) Cut to "Sell" at Zacks Investment ResearchMyovant Sciences (NYSE:MYOV) Cut to "Sell" at Zacks Investment Research
marketbeat.com - November 18 at 5:20 AM
Myovant Sciences (NYSE:MYOV) Downgraded by ValuEngine to HoldMyovant Sciences (NYSE:MYOV) Downgraded by ValuEngine to Hold
marketbeat.com - October 1 at 2:21 AM
Myovant Sciences (NYSE:MYOV) Lifted to "Buy" at ValuEngineMyovant Sciences (NYSE:MYOV) Lifted to "Buy" at ValuEngine
marketbeat.com - August 27 at 2:15 AM
Myovant Sciences (NYSE:MYOV) Upgraded to Hold by Zacks Investment ResearchMyovant Sciences (NYSE:MYOV) Upgraded to Hold by Zacks Investment Research
marketbeat.com - August 15 at 3:10 AM
Myovant Sciences (NYSE:MYOV) Stock Price Up 7% After Analyst UpgradeMyovant Sciences (NYSE:MYOV) Stock Price Up 7% After Analyst Upgrade
marketbeat.com - June 24 at 1:53 PM
Myovant Sciences (NYSE:MYOV) Hits New 12-Month High at $23.11Myovant Sciences (NYSE:MYOV) Hits New 12-Month High at $23.11
americanbankingnews.com - November 27 at 11:47 AM
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary EndpointUrovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
businesswire.com - November 24 at 6:36 PM
Myovant Sciences (NYSE:MYOV) Stock Price Up 5.2%Myovant Sciences (NYSE:MYOV) Stock Price Up 5.2%
americanbankingnews.com - November 23 at 10:38 PM
Myovant Sciences to Present at Upcoming December Investor ConferencesMyovant Sciences to Present at Upcoming December Investor Conferences
finance.yahoo.com - November 23 at 7:32 AM
Insider Selling: Myovant Sciences Ltd. (NYSE:MYOV) Insider Sells 750 Shares of StockInsider Selling: Myovant Sciences Ltd. (NYSE:MYOV) Insider Sells 750 Shares of Stock
americanbankingnews.com - November 19 at 6:00 PM
Breakeven On The Horizon For Myovant Sciences Ltd. (NYSE:MYOV)Breakeven On The Horizon For Myovant Sciences Ltd. (NYSE:MYOV)
finance.yahoo.com - November 18 at 11:37 AM
Frank Karbe Sells 750 Shares of Myovant Sciences Ltd. (NYSE:MYOV) StockFrank Karbe Sells 750 Shares of Myovant Sciences Ltd. (NYSE:MYOV) Stock
americanbankingnews.com - November 17 at 9:04 PM
Myovant Sciences (NYSE:MYOV) Trading 6.7% Higher Myovant Sciences (NYSE:MYOV) Trading 6.7% Higher
americanbankingnews.com - November 17 at 7:33 PM
Stock Traders Buy High Volume of Myovant Sciences Call Options (NYSE:MYOV)Stock Traders Buy High Volume of Myovant Sciences Call Options (NYSE:MYOV)
americanbankingnews.com - November 14 at 5:50 PM
Myovant Sciences (NYSE:MYOV) Issues  Earnings Results, Beats Expectations By $0.03 EPSMyovant Sciences (NYSE:MYOV) Issues Earnings Results, Beats Expectations By $0.03 EPS
americanbankingnews.com - November 13 at 5:25 PM
Myovant Sciences Ltd. 2020 Q2 - Results - Earnings Call PresentationMyovant Sciences Ltd. 2020 Q2 - Results - Earnings Call Presentation
seekingalpha.com - November 12 at 4:22 PM
Myovant Sciences (MYOV) CEO Lynn Seely on Q2 2020 Results - Earnings Call TranscriptMyovant Sciences' (MYOV) CEO Lynn Seely on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 1:46 PM
Recap: Myovant Sciences Q2 EarningsRecap: Myovant Sciences Q2 Earnings
benzinga.com - November 12 at 8:45 AM
Myovant Sciences Ltd. to Host Earnings CallMyovant Sciences Ltd. to Host Earnings Call
finance.yahoo.com - November 12 at 8:45 AM
Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020
finance.yahoo.com - November 12 at 8:45 AM
Myovant Sciences: More Than Meets The EyeMyovant Sciences: More Than Meets The Eye
seekingalpha.com - November 11 at 10:44 PM
Myovant Sciences (NYSE:MYOV) Trading Up 5.7%Myovant Sciences (NYSE:MYOV) Trading Up 5.7%
americanbankingnews.com - November 11 at 8:03 PM
Myovant Sciences Ltd. (NYSE:MYOV) Receives Average Rating of "Buy" from AnalystsMyovant Sciences Ltd. (NYSE:MYOV) Receives Average Rating of "Buy" from Analysts
americanbankingnews.com - November 10 at 3:38 PM
Myovant Sciences Ltd. (NYSE:MYOV) Expected to Post Earnings of -$0.81 Per ShareMyovant Sciences Ltd. (NYSE:MYOV) Expected to Post Earnings of -$0.81 Per Share
americanbankingnews.com - November 9 at 11:14 PM
The Sell-Off In Myovant Is Unjustified By FundamentalsThe Sell-Off In Myovant Is Unjustified By Fundamentals
seekingalpha.com - November 9 at 5:38 AM
Most Admired CEOs: At Myovant, Lynn Seely is eager to explore new worlds (Video)Most Admired CEOs: At Myovant, Lynn Seely is eager to 'explore new worlds' (Video)
bizjournals.com - November 6 at 12:30 PM
Myovant Sciences (NYSE:MYOV) Trading Up 6.4%Myovant Sciences (NYSE:MYOV) Trading Up 6.4%
americanbankingnews.com - November 4 at 8:19 PM
Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020
finance.yahoo.com - November 2 at 1:27 PM
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine FibroidsMyovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
finance.yahoo.com - October 21 at 1:11 PM
Myovant Sciences Appoints Ryan Crowe as Vice President, Investor RelationsMyovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations
nasdaq.com - October 16 at 12:05 PM
Investors skittish with Myovant Sciences after relugolix fails to top comparator drug on key survival endpoint in prostate cancer studyInvestors skittish with Myovant Sciences after relugolix fails to top comparator drug on key survival endpoint in prostate cancer study
seekingalpha.com - October 3 at 8:02 AM
SHAREHOLDER ALERT: Investigation of Myovant Announced by Holzer & Holzer, LLCSHAREHOLDER ALERT: Investigation of Myovant Announced by Holzer & Holzer, LLC
marketwatch.com - September 29 at 5:33 PM
Mid-Afternoon Market Update: Gold Rises 1%; Myovant Sciences Shares PlungeMid-Afternoon Market Update: Gold Rises 1%; Myovant Sciences Shares Plunge
benzinga.com - September 29 at 5:33 PM
Myovant slumps 20% on disappointing relugolix data in prostate cancerMyovant slumps 20% on disappointing relugolix data in prostate cancer
seekingalpha.com - September 29 at 12:33 PM
Why Myovants Stock Is Trading Lower TodayWhy Myovant's Stock Is Trading Lower Today
benzinga.com - September 29 at 12:33 PM
Stock Alert: Myovant Sciences Slides 24% On Relugolix DataStock Alert: Myovant Sciences Slides 24% On Relugolix Data
nasdaq.com - September 29 at 12:33 PM
Is the Options Market Predicting a Spike in Myovant Sciences (MYOV) Stock?Is the Options Market Predicting a Spike in Myovant Sciences (MYOV) Stock?
nasdaq.com - September 25 at 1:12 PM
Myovant Sciences Launches "Forward for Health Equity" Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine FibroidsMyovant Sciences Launches "Forward for Health Equity" Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
marketwatch.com - September 23 at 8:56 PM
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine FibroidsMyovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
finance.yahoo.com - September 23 at 10:55 AM
Myovant Sciences relugolix triplet therapy shows positive action in uterine fibroid studyMyovant Sciences' relugolix triplet therapy shows positive action in uterine fibroid study
seekingalpha.com - September 14 at 12:08 PM
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational StudyMyovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
finance.yahoo.com - September 14 at 12:08 PM
Is Myovant Sciences (NYSE:MYOV) 152% Share Price Increase Well Justified?Is Myovant Sciences' (NYSE:MYOV) 152% Share Price Increase Well Justified?
finance.yahoo.com - August 21 at 12:03 AM
Is Myovant Sciences' (NYSE:MYOV) 152% Share Price Increase Well Justified?Is Myovant Sciences' (NYSE:MYOV) 152% Share Price Increase Well Justified?
finance.yahoo.com - August 20 at 2:02 PM
FDA accepts Myovant application for relugolix for uterine fibroidsFDA accepts Myovant application for relugolix for uterine fibroids
seekingalpha.com - August 17 at 1:55 PM
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine FibroidsMyovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
finance.yahoo.com - August 17 at 8:55 AM
Myovant Sciences: Fiscal 1Q Earnings SnapshotMyovant Sciences: Fiscal 1Q Earnings Snapshot
finance.yahoo.com - August 11 at 5:06 PM
Myovant to receive additional financing from Sumitomo Dainippon PharmaMyovant to receive additional financing from Sumitomo Dainippon Pharma
seekingalpha.com - August 5 at 9:28 AM
Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion PharmaceuticalsMyovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
finance.yahoo.com - August 5 at 9:28 AM
As it seeks prostate cancer drug approval, Peninsula drug maker targets a forgotten market: Black menAs it seeks prostate cancer drug approval, Peninsula drug maker targets a forgotten market: Black men
www.bizjournals.com - July 6 at 11:31 PM
BRIEF-Myovant Sciences Presents Additional Data On Relugolix Combination TherapyBRIEF-Myovant Sciences Presents Additional Data On Relugolix Combination Therapy
www.reuters.com - July 6 at 1:31 PM
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition StudyMyovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
finance.yahoo.com - July 6 at 1:31 PM
Myovant Sciences Ltd. (MYOV): Hedge Fund Sentiment UnchangedMyovant Sciences Ltd. (MYOV): Hedge Fund Sentiment Unchanged
finance.yahoo.com - July 6 at 12:25 AM
BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate CancerBlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer
finance.yahoo.com - June 30 at 11:21 AM
Myovants Endometriosis Pain Drug Meets Goal in Study, Stock UpMyovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up
finance.yahoo.com - June 25 at 1:31 PM
Myovant Sciencess relugolix combo successful in second late-stage endometriosis studyMyovant Sciences's relugolix combo successful in second late-stage endometriosis study
seekingalpha.com - June 23 at 6:01 PM
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.